Immunoprecise advances universal dengue vaccine, confirming safety, immune activation, and structural stability using its lensai™ platform powered by patented hyft® technology

Austin, texas--(business wire)---- $ipa #ai--immunoprecise (nasdaq: ipa), a leader in ai-driven biotherapeutics, provides a significant update following its june 5, 2025, press release immunoprecise announces ai-driven breakthrough in universal dengue vaccine discovery. this new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also.
UVV Ratings Summary
UVV Quant Ranking